SYDNEY, April 14,
2023 /PRNewswire/ -- Kazia Therapeutics Limited
(NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development
company, is pleased to have received notification from the Listing
Qualifications Staff (the "Staff") of the Nasdaq Stock Market LLC
(Nasdaq) that it has regained compliance with the minimum bid price
requirement under Nasdaq Listing Rule 5550(a)(2).
The company previously received notification from the Staff on
December 9, 2022, that its American
Depository Shares (ADSs) were not in compliance with Nasdaq's
minimum bid price requirement, having closed at a price below
US$ 1.00 per share for thirty
consecutive business days.
Nasdaq Listing Rule 5550(a)(2) requires listed securities to
maintain a minimum bid price of at least US$
1.00 per share, and failure to do so for a period of 30
consecutive business days triggers a deficiency notice. Under
Nasdaq Listing Rule 5810(c)(3)(A), the company has 180 calendar
days from the date of the notice to cure the deficiency. If at any
time during this period the bid price of the company's ADSs closes
at or above US$ 1.00 per share for a minimum of ten consecutive
business days, the company will regain compliance with the minimum
bid requirement.
On April 13, 2023, the company
received written notification from Nasdaq that the company had
regained compliance with Nasdaq Listing Rule 5550(a)(2) because the
Staff determined that in the ten consecutive business days, from
March 29, 2023 to April 12, 2023, the closing bid price of the
company's ADSs has been at $1.00 per
share or greater..
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an
oncology-focused drug development company, based in Sydney, Australia.
Our lead program is paxalisib, a brain-penetrant inhibitor of
the PI3K / Akt / mTOR pathway, which is being developed to treat
multiple forms of brain cancer. Licensed from Genentech in late
2016, paxalisib is or has been the subject of ten clinical trials
in this disease. A completed phase II study in glioblastoma
reported promising signals of efficacy in 2021, and a pivotal study
for registration, GBM AGILE, is ongoing, with final data expected
in CY2023. Other clinical trials are ongoing in brain metastases,
diffuse midline gliomas, and primary CNS lymphoma, with several of
these having reported encouraging interim data.
Paxalisib was granted Orphan Drug Designation for glioblastoma
by the US FDA in February 2018, and
Fast Track Designation for glioblastoma by the US FDA in
August 2020. In addition, paxalisib
was granted Rare Pediatric Disease Designation and Orphan
Designation by the US FDA for DIPG in August
2020, and for atypical teratoid / rhabdoid tumours (AT/RT)
in June 2022 and July 2022, respectively.
Kazia is also developing EVT801, a small-molecule inhibitor of
VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to
be active against a broad range of tumour types and has provided
compelling evidence of synergy with immuno-oncology agents. A phase
I study commenced recruitment in November
2021.
For more information, please visit www.kaziatherapeutics.com or
follow us on Twitter @KaziaTx.
For More Information, Please Contact:-
Jane Lowe
IR Department
jane.lowe@irdepartment.com.au
Phone: +61 411 117 774
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kazia-regains-compliance-with-nasdaq-minimum-bid-price-requirement-301797187.html
SOURCE Kazia Therapeutics Limited